Walter EA, Elmar J, Dolan MJ; Conference on Retroviruses and Opportunistic Infections.
Program Abstr 4th Conf Retrovir Oppor Infect Conf Retrovir Oppor Infect 4th 1997 Wash DC. 1997 Jan 22-26; 4th: 154 (abstract no. 487).
Wilford Hall Medical Center, Lackland AFB, San Antonio, TX.
In vitro data shows that IgA can neutralize laboratory strains of HIV, but is also capable of enhancing HIV entry into monocytes. To date, no study has determined the in vivo effect of IgA deficiency on the rate of HIV disease progression. We prospectively studied the time to first opportunistic infection and the survival time of 3063 HIV seropositive patients in the military natural history study and we identified 7 IgA deficient HIV-seropositive individuals. The mean IgA level was 2.38 mg/dl in the IgA deficient patients and 259 mg/dl in the control patients. The incidence of IgA deficiency (1/438) seen in the military HIV seropositive patient population was not significantly different than that reported in the American blood bank cohort(1/600). We compared the clinical course of HIV disease over a mean of 9 1/2 years (range 3-10) of the Ig A deficient patients to a control group of HIV seropositive patients matched for age, race, sex, baseline CD4 count and year of diagnosis. There was no significant difference in the time to AIDS-defining diagnosis (p=0.90 log rank test) or time to death (p=0.21) between the IgA deficient patients and the controls. Conclusion: IgA deficiency is not over represented in this HIV seropositive military population compared to the blood donor population. IgA deficiency does not appear to be associated with a more rapid progression to AIDS-defining diagnosis or death.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- CD4 Lymphocyte Count
- Case-Control Studies
- Disease Progression
- HIV Infections
- HIV Seropositivity
- Humans
- IgA Deficiency
- Immunoglobulins
- In Vitro
- Incidence
Other ID:
UI: 102223362
From Meeting Abstracts